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INTRINSIC PATHWAY-DEPENDENT ACTIVATED CLOTTING TIME IS NOT RELIABLE FOR 
MONITORING ANTICOAGULATION DURING CARDIOPULMONARY BYPASS IN NEONATES 
Y. J. Gu, MD, a R. J. Huyzen, MD, b and W. van Oeveren, MD, a Groningen, The Netherlands 
The conventional ctivated clotting time (ACT) stim- 
ulated by celite is often prolonged during neonatal or 
pediatric cardiopulmonary bypass operations. 1'2 This 
prolonged ACT may lead to insufficient use of heparin 
during bypass and result in serious consequences such 
as intravascular coagulation after the operation. 3 Dilu- 
tion of the clotting factors because of high-degree 
hemodilution during bypass is often blamed for the 
prolongation of ACT, 2' 4 but it is still unknown whether 
the total clotting capacity in the circulating blood is 
similarly affected by the extreme hemodilution. Because 
the celite ACT is a clotting test dependent on the 
intrinsic pathway, we postulate that it is the intrinsic 
pathway (rather than the extrinsic and the common 
pathways) that fails to respond properly under high- 
degree hemodilution during neonatal bypass opera- 
tions. 
As a first step, we studied the in vitro effect of 
dilution on celite ACT by using heparinized blood 
taken from 10 adults having coronary artery bypass. The 
samples were taken after a 300 IU/kg dose of bovine 
heparin was given before the start of bypass. These 
patients received no drugs known to affect clotting and 
had a normal clotting profile before the operation. 
Blood samples were diluted in the laboratory to 25%, 
50%, and 75% with saline solution or were left undi- 
luted as control samples. Three different types of 
stimuli were used to initiate clotting: celite (final con- 
centration 3 mg/ml) stimulating clotting through the 
intrinsic pathway, rabbit brain thromboplastin (final 
concentration 4 mg/ml) through the extrinsic pathway, 
and high-dose thrombin (final concentration 9 U/ml) 
through the common pathway. All measurements were 
performed with a Hemochron 8000 machine (Interna- 
tional Technidyne Co., Edison, N.J.). An ACT longer 
than 1000 seconds was stopped and recorded as 1000 
seconds. In blood samples stimulated by celite, ACT 
was prolonged significantly when the blood was diluted 
to 75% compared with the ACT of control samples (p < 
0.01), whereas in samples timulated by thromboplastin 
no significant change was observed. Furthermore, in 
blood samples stimulated by thrombin a significant 
reduction of ACT was found in proportion to the 
dilution of blood (p < 0.01, Table I). These results 
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suggest that it is the intrinsic pathway but not the 
extrinsic pathway and common pathway that is impaired 
to cause clotting in the test tubes under extreme 
hemodilution. These results also suggest that fibrinogen 
is not a limiting factor during extreme dilution if 
clotting is triggered by either the extrinsic pathway or 
the common pathway. 
Clinically, we compared the celite ACT with the 
high-dose thrombin time (Hemochron machine; Inter- 
national Technidyne) during neonatal cardiopulmonary 
bypass (n = 10) after approval by the hospital ethical 
committee and written informed consent from the 
parents. These newborn infants had an average age of 8 
days (1 to 17 days) and a mean body weight of 3.6 kg 
(3.1 to 4.5 kg). Before bypass, anticoagulation was 
achieved by a 300 IU/kg dose of bovine heparin and a 
further 1000 IU in the prime solution. The extracorpo- 
real circuit was primed with Ringer's solution and 
human albumin with additional red blood cell concen- 
trates. The average hemoglobin level at 30 minutes of 
bypass was 52.8 _+ 8.8 gm/L. Almost all the celite ACTs 
were longer than 1000 seconds during bypass, whereas 
the concentration of heparin (measured by antifactor X
assay) was gradually declining. By contrast, the high- 
dose thrombin time shortened gradually toward the end 
of bypass (Table II). 
Celite ACT is based on clot formation through the 
intrinsic clotting pathway, which is dependent on sev- 
eral clotting factors in the early clotting cascade, s The 
baseline levels of intrinsic clotting factors, such as 
factor XII and factor XI, are much lower in neonates 
than in adults. 6 Moreover, the degree of hemodilution 
during bypass is higher in neonates than in adults. 7
Thus the intrinsic clotting pathway in neonates is too 
weak to be triggered in the extremely diluted blood, so 
that the celite ACT is prolonged and less heparin is 
needed. On the other hand, the metabolism of heparin 
during bypass is more rapid in children than in adults, 2
and these neonates, especially those with cyanosis, are 
likely to have extensive exposure of blood in the 
thoracic cavity, which is known to further consume 
heparin, s All these factors taken together, these neo- 
nates are facing a great risk of receiving insufficient 
anticoagulation during bypass if their condition is mon- 
itored by the celite ACT. 
Thus the conventional celite ACT, in which clotting is 
stimulated from the intrinsic pathway, is not a reliable test 
for monitoring anticoagulation for neonatal or pediatric 
cardiopulmonary b pass during a high degree of hemodi- 
lution. We recommend that tests stimulating the common 
clotting pathway, such as the high-dose thrombin time or 
other reliable methods, be used to prevent the empiric use 
of heparin for neonates. 
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Table  I. In vitro effect of  hemodilution on whole blood clotting time (seconds) 
Degree of hemodilution 
Stimulus Pathway Controls 25% 50% 75% 
Celite Intrinsic 459 _+ 75 442 _+ 67 488 _+ 94 951 ± 154" 
Thromboplastin extrinsic 294 ± 29 251 + 21 277 ± 34 355 _+ 61 
Thrombin common 165 ± 51 113 + 58 91 -- 34 55 ± 19 
Values are expressed asmean -+ standard eviation. 
*In 9 of 10 samples clotting time was more than 1000 seconds 
Tab le  I I .  Clinical observation in neonates undergoing cardiac operations 
After 5 rain 30 rain 60 rain 90 rain End 
heparinization CPB CPB CPB CPB CPB 
ACTc (sec) 669 _+ 233 980 + 63* 992 + 63* 995 ± 15" 1000 -- 0 774 -- 214 
HiTT (sec) 168 _+ 58 163 ± 80 132 ± 31 132 _+ 53 118 _+ 53 95 ± 30 
Heparin (IU/ml) 2.7 _+ 0.4 1.2 ± 0.5 1.1 ± 0.5 1.3 -- 0.4 1.2 +_ 0.5 0.8 ± 0.3 
Values are expressed asmean + standard eviation. ACTc, Celite activated clotting time; HiTT, high-dose thrombin time; CPB, cardiopulmonary bypass. 
*In 9 of 10 samples ACTc was greater than 1000 seconds. 
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THE USE OF BIOLOGIC GLUE FOR BETTER ADHESIONS BETWEEN THE SKELETAL MUSCLE 
FLAP AND THE MYOCARDIUM AND FOR INCREASING CAPILLARY INGROWTH 
Valeri Chekanov, MD, PhD, Victor Nikolaychik, MD, PhD, and Guennady Tchekanov, MD, Milwaukee, Wis. 
To date, dynamic ardiomyoplasty relies on use of a properly 
conditioned, adequately contracting autogenous muscle flap for 
the correction of myocardial insutficiency. Despite its advan- 
tages, cardiomyoplasty has some unresolved problems: (1) poor 
angiogenic potential of the ischemic, traumatized skeletal mus- 
cle and damaged myocardium and (2) incomplete contact 
between the mobile myocardial wall and the transplanted flap. 
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These problems manifest hemselves after the opertion. The 
vascular supply is not reintroduced until 6 to 8 months after the 
operation. Some patients have died of recurrent myocardial 
infarction 3 to 5 months after cardiomyoplasty, before a new 
blood supply from the skeletal muscle to the myocardium had 
been established. I'2 This is the situation that needs to be 
resolved. Cardiomyoplasty done with skeletal muscle can pro- 
vide capillary ingro,m~h to the myocardium, but it may be too 
late for some patients. 
A novel approach to resolving these problems involves 
"therapeutic angiogenesis." Nine weeks after a modified 
fibrin glue (containing endothelial cell growth factor) has 
been applied between the aorta and the left ventricular 
myocardium, angiographic and histologic investigations 
have shown newly grown vascular structures between 
